Shots:

• The P-III (DINAMO) trial evaluating the efficacy & safety of Jardiance (10/25mg) and Tradjenta (5mg) vs PBO in 175 children and adolescents aged 10-17yrs. with T2D
• The trial met its 1EPs i.e., Jardiance (SGLT2 inhibitor) showed a reduction in HbA1c while 0.84% reduction @26wk. with the addition of Jardiance to other baseline treatments (diet, exercise, metformin & insulin). Additionally, the overall safety data were consistent with prior results with a well-established safety profile
• The 2EPs also showed a reduction in fasting plasma glucose @26wk., a numerical reduction of 0.34% were seen. The results were submitted to a peer-reviewed journal

Ref: Eli Lilly | Image: Eli Lilly